Trialect

+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Verified

Notice of Special Interest (NOSI): Impacts of Psychedelic and Dissociative Drug Policy Changes on Public Health Outcomes

National Institutes of Health

The purpose of this notice of special interest (NOSI) is to inform potential applicants to the National Institute on Drug Abuse ( NIDA ) of special interest in grant applications that examine the impact of changing state and local psychedelic and dissociative drug policies.

Psychedelic and dissociative drugs (also commonly known as hallucinogens) are a class of psychoactive substances that alter people's perception, mood, and cognitive processes. Whereas many psychedelic drugs are derived from plants and fungi, others are made in labs (i.e., “synthetic”). This category of substances includes psychedelic drugs that primarily influence the way the brain processes the chemical serotonin (e.g., psilocybin; LSD; N, N-Dimethyltryptamine (DMT); mescaline; and NBOMes); dissociative drugs that primarily affect how the brain processes the chemical glutamate (e.g., ketamine and PCP); and other drugs which cause psychedelic and/or dissociative effects (e.g., MDMA, ibogaine, and salvia).

The Drug Enforcement Administration (DEA) has scheduled most psychedelic and dissociative drugs as Schedule I Controlled Substances. (This does not include Ketamine which is a Schedule III drug). Substances in this schedule have no currently accepted medical use in the U.S., are unsafe even when used under medical supervision, and have a high potential for abuse. Even so, in 2021, 2.6% of individuals ages 12 and older and 8% of young adults ages 19 to 30 reported using “hallucinogens” in the past 12 months.

Recently, state policy around psychedelic and dissociative drugs also has been changing rapidly. States, and in some cases cities, have taken a variety of approaches that include legalization, decriminalization, reduced penalties, and more. Between January 2019 and September 2022, 25 states considered 74 different bills dealing with psychedelic drugs. Two states have enacted statutes legalizing and regulating psychedelics. In November 2020, Oregon became the first state to legalize the manufacturing, transportation, delivery, sale, and purchase of psilocybin products and the provision of psilocybin-assisted services. On January 2, 2023, the state began accepting applications for licensure and expect new psilocybin service centers to begin offering psilocybin services in 2023. Similarly, Colorado legalized psychedelics on November 8, 2022, allowing for the creation of state sanctioned “healing centers” with the licensing process beginning by September 2024. Although the healing centers are currently only approved to distribute psilocybin and psilocyn, this would be expanded to include DMT, ibogaine, and mescaline (excluding peyote) in June 2026.

This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through September 8, 2026.

NOT-DA-24-010

Specialties

Drug Delivery

Mental Health

Others

Health Policy & Ethics

Neurosciences

Eligibility Requirements

This notice applies to due dates on or after October 5, 2023 and subsequent receipt dates through September 8, 2026.

Submit applications for this initiative using one of the following notice of funding opportunity (NOFO) or any reissues of these announcements through the expiration date of this notice.

Sponsor Details

Sponsor Institute/Organizations: National Institutes of Health

Sponsor Type:

Address: National Institutes of Health; 31 Center Drive; MSC 2220; Bethesda; MD 20892-2220; USA

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity